Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group

Table 5 Summary of monitoring assessments to be made during ERT

Test	Frequency
Manual muscle testing
Quantitative muscle testing
Vital capacity	Every 6 months
Time on ventilation daily (invasive or noninvasive)	Every 6 months
Six-minute walk test
Quality of life measurement
Creatine kinase	Every 3 months in the first year post-diagnosis
Alanine transaminase	Every 3 months in the first year post-diagnosis
Aspartate transaminase	Every 6 months if stable on ERT
Antibody titers
Electrocardiography	At baseline and repeated regularly if clinically indicated
Echocardiography
DEXA (bone mineral density)
Audiology assessment

ISSN: 1471-2377